Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)
6 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Publication of Manuscript from the PNOC015 (a.k.a….
6 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Publication of Manuscript from the PNOC015 (a.k.a….
HAMPTON, N.J., July 06, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that…
HAMPTON, N.J., July 06, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that…
Management team to speak at 2nd In Vivo Engineering of Therapeutic Cells Summit and 8th…
Management team to speak at 2nd In Vivo Engineering of Therapeutic Cells Summit and 8th…
LEXINGTON, Mass., July 06, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
LEXINGTON, Mass., July 06, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
SANTA ANA, Calif. and THE WOODLANDS, Texas, July 06, 2023 (GLOBE NEWSWIRE) — NKGen Biotech…
SANTA ANA, Calif. and THE WOODLANDS, Texas, July 06, 2023 (GLOBE NEWSWIRE) — NKGen Biotech…
ROCKAWAY, N.J., July 06, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine…
ROCKAWAY, N.J., July 06, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine…
· Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years…
· Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years…
NEW YORK and LONDON, July 06, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
NEW YORK and LONDON, July 06, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
WARREN, N.J., July 06, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company”…
WARREN, N.J., July 06, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company”…
Met all primary endpoints: Vaccine was well-tolerated with robust immunogenicity Continue to expect topline data…
LOS ANGELES, July 06, 2023 (GLOBE NEWSWIRE) — ViaDerma, Inc. (OTC Pink: VDRM) is very…
Met all primary endpoints: Vaccine was well-tolerated with robust immunogenicity Continue to expect topline data…